A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
NCT04035434 · TERMINATED · Phase 2
ReadTheTrial indexes 1 studies for B Cell Malignancy. The most common development stage is Phase 2 (1 trials). Each trial page translates ClinicalTrials.gov eligibility, outcomes, and design into patient-friendly language so you can compare options quickly.
1 clinical trials found for B Cell Malignancy.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 1 | 100% |
There are 1 clinical trials listed for B Cell Malignancy. These span various phases from early safety studies to post-approval monitoring. Browse the trial listings below for details.
Look for trials with "Recruiting" status in the listings below, or visit our recruiting page to filter by condition. Each trial page includes decoded eligibility criteria to help you determine if you qualify.
Current B Cell Malignancy trials are distributed across: Phase 2 (1).